Catalogo dei prodotti della ricerca

VISENTINI, MARCELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.874
EU - Europa 1.158
AS - Asia 460
SA - Sud America 26
AF - Africa 20
OC - Oceania 3
Totale 4.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.850
IT - Italia 609
SE - Svezia 211
SG - Singapore 199
IN - India 136
CN - Cina 101
FI - Finlandia 66
UA - Ucraina 50
BG - Bulgaria 43
DE - Germania 41
GB - Regno Unito 37
AR - Argentina 22
IE - Irlanda 19
CA - Canada 17
FR - Francia 14
RO - Romania 13
TG - Togo 13
TR - Turchia 13
BE - Belgio 8
NL - Olanda 8
PL - Polonia 8
RU - Federazione Russa 8
NO - Norvegia 6
CH - Svizzera 5
MX - Messico 5
ZA - Sudafrica 5
LU - Lussemburgo 4
CL - Cile 3
IR - Iran 3
AU - Australia 2
BZ - Belize 2
GR - Grecia 2
HK - Hong Kong 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BR - Brasile 1
EE - Estonia 1
EG - Egitto 1
HR - Croazia 1
JP - Giappone 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
TN - Tunisia 1
VN - Vietnam 1
Totale 4.541
Salva come PNG Salva come JPEG
Città #
Fairfield 441
Rome 283
Chandler 279
Ashburn 274
Woodbridge 202
Seattle 173
Wilmington 165
Houston 154
Cambridge 150
Singapore 136
Princeton 91
Beijing 84
Ann Arbor 80
San Paolo di Civitate 75
Plano 52
Lawrence 49
San Diego 44
Sofia 41
Boston 39
Millbury 33
Santa Clara 29
Dearborn 28
Andover 27
New York 23
Dublin 19
Los Angeles 19
Federal 16
Helsinki 16
Fiuggi 14
Toronto 14
Lomé 13
Falls Church 12
Jacksonville 11
Milan 11
Norwalk 11
Bremen 10
Istanbul 10
Lappeenranta 9
Bari 8
Brussels 8
Fremont 8
Boardman 7
Pune 7
Southend 7
Buenos Aires 6
Buffalo 6
Dallas 6
Gelsenkirchen 5
Verona 5
Washington 5
Bergen 4
Bühl 4
Campobasso 4
Hefei 4
Mannheim 4
Mexico City 4
Phoenix 4
San Jose 4
Bologna 3
Ciampino 3
Frankfurt am Main 3
Gavello 3
Heidelberg 3
Izmir 3
Kilburn 3
Las Vegas 3
Leawood 3
London 3
Muizenberg 3
Ottawa 3
Padova 3
Redwood City 3
Sacramento 3
San Mateo 3
Stockholm 3
Afragola 2
Albuquerque 2
Athens 2
Avigliano 2
Bagheria 2
Belgrade 2
Belize City 2
Bucharest 2
Capannori 2
Carloforte 2
Chions 2
Des Moines 2
Florence 2
Genoa 2
Gioia Tauro 2
Groningen 2
Guangzhou 2
Hong Kong 2
Hounslow 2
Hyderabad 2
Jinan 2
Lamezia Terme 2
Lexington 2
Livorno 2
Lugano 2
Totale 3.348
Salva come PNG Salva come JPEG
Nome #
Dysregulated extracellular signal-regulated kinase signaling associated with impaired B-cell receptor endocytosis in patients with common variable immunodeficiency 116
Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA covid-19 vaccine 114
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 99
The VH1-69-expressing marginal zone B cells expanded in HCV-associated mixed cryoglobulinemia display proliferative anergy irrespective of CD21low phenotype. 98
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 94
Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis 88
A LYMPHOTACTIN-PRODUCING MONOCLONAL T-CELL LYMPHOPROLIFERATIVE DISORDER WITH EXTREME LYMPHOCYTOPENIA AND PROGRESSIVE LEUKOENCEPHALOPATHY 86
The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy. 85
Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia. 85
Clonal B cells of HCV-associated mixed cryoglobulinemia patients contain exhausted marginal zone-like and CD21 low cells overexpressing Stra13 82
Persistence of a Large Population of Exhausted Monoclonal B cells in Mixed Cryoglobuliemia After the Eradication of Hepatitis C Virus Infection 77
DEC1/STRA13 is a key negative regulator of activation-induced proliferation of human B cells highly expressed in anergic cells 77
CD21low B cells in systemic sclerosis: a possible marker of vascular complications 76
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study 75
From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals? 75
Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: The yin and yang of HCV-driven lymphoproliferation and autoimmunity 75
Clinical course, management, and platelet activity assessment of splanchnic VITT: a case report 75
A simultaneous occurrence of Tolosa-Hunt syndrome and fibrillary glomerulonephritis: a case report 73
Reduced lysosomal acid lipase activity in blood and platelets is associated with nonalcoholic fatty liver disease 73
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 73
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 71
Regression of Systemic Lupus Erythematosus After Development of an Acquired Toll-like Receptor Signaling Defect and Antibody Deficiency 70
Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration 70
HBV messing with the B-cell genome leads to DLBCL 70
Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. 70
Adequate Patient's Outcome Achieved with Short Immunoglobulin Replacement Intervals in Severe Antibody Deficiencies 69
Distinct platelet crosstalk with adaptive and innate immune cells after adenoviral and mRNA vaccination against SARS-CoV-2 68
Intravenous immunoglobulin replacement therapy in common variable immunodeficiency induces B cell depletion through differentiation into apoptosis-prone CD21low B cells 68
Circulating CD21(low) B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells 67
CD21-/low B cells associate with joint damage in rheumatoid arthritis patients 66
Editorial: Immunoglobulin therapy in the 21st century - The dark side of the moon 64
Persistence of pathogenic B cell clones and relapse of cryoglobulinemic vasculitis in HCV-cured patients 64
Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer 61
Switched CD21–/low B cells with an antigen-presenting phenotype in the infant thymus 61
Long term outcome of WHIM syndrome in 18 patients: high risk of lung disease and HPV-related malignancies. 61
Different genomic imbalances in low- and high-grade HCV-related lymphomas 60
Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis 60
Increased von willebrand factor platelet-binding capacity is related to poor prognosis in Covid-19 patients 59
Hepatitis B virus causes mixed cryoglobulinaemia by driving clonal expansion of innate B-cells producing a VH1-69-encoded antibody 59
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection 58
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 58
Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinemy 57
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 57
Efficacy of low-dose rituximab for mixed cryoglobulinemia 57
Correction to: Reduced lysosomal acid lipase activity in blood and platelets Is associated with nonalcoholic fatty liver disease 56
SIMULTANEA PRESENTAZIONE DI GLOMERULONEFRITE FIBRILLARE E SINDROME DI TOLOSA-HUNT 55
CD21 low B cells are predictive markers of new digital ulcers in systemic sclerosis 55
Sterile abscesses complicating monoclonal gammopathy of undetermined significance. 54
Hepatitis B virus-related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review. 52
Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study 51
B-cell memory defect in a SLE induced a severe antibody, stable clinical remission and succesful renal transplantation 50
Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects 50
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 50
Clinico-immunologic outcomes of HCV-cured cryoglobulinemia: lower relapse rate with interferon-based than interferon-free therapy 50
Telomere-dependent replicative senescence of B and T cells from patients with type 1a common variable immunodeficiency 46
The CD21low B Cells Expanded in Common Variable Immunodeficiency do not Differentiate to Antibody Producing Cells After Stimulation of Toll-like Receptor 9 Because of a Reduced Proliferative Potential 41
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia 41
Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia 41
Persistent Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Following Virus Eradication After Direct-Acting Antiviral Therapy Reply 40
Cryoglobulins: putative effectors of adaptive immune response 39
Relapse of HCV-Cryoglobulinemic Vasculitis Following Sustained Viral Response after Interferon-free Direct-Acting Antivirals 39
Safety and effectiveness of biosimilar of Rituximab CT‐P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar) 38
Defective proliferative response of B-lymphocytes upon stimulation of TLR7 and TLR9 in common variable immune deficiency 37
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 34
Rheumatoid factor-producing CD21low anergic clonal B-cells in essential mixed cryoglobulinaemia: a model for autoantigen-driven pathogenesis of infectious and non-infectious cryoglobulinaemias 33
Breakthrough infections after Covid-19 vaccinations do not elicit platelet hyper-activation and associate with high platelet-lymphocyte and low platelet-neutrophil aggregates 32
Serological response and relationship with gender-sensitive variables among healthcare workers after SARS-CoV-2 vaccination 30
Serum and urine free light chains measurements in patients with systemic sclerosis: novel biomarkers for disease activity 28
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders 28
COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis 26
Ig levels and B cell differenziative capacity predict the risk of acute infections in CVID 26
Which IgG Trough Levels are Necessary to Protect Against Infections? Results of the Prospective Study on XLA and CVID 26
Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases 26
Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia 25
Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy 24
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 24
Relapsing cellulitis and bacteriemia due to a long lasting (10 years) Campylobacter coli infection in a XLA patient 23
Evaluation of the Benefit/Cost/Safety Profile of Low-dose Anti-CD20 Monoclonal Antibody (Rituximab) Treatment for Refractory Mixed Cryoglobulinemia 22
NEFRITE LUPICA E TERAPIA IMMUNOSOPPRESSIVA: REMISSIONE DEL LES DOPO DEFICIT ACQUISITO DELLE CELLULE B DELLA MEMORIA 22
The effect of SARS-CoV-2 vaccination on B-cell phenotype in systemic sclerosis patients 21
The Marginal Zone B Cells Clonally Expanded in Hepatitis C-Related Mixed Cryoglobulinemia Display the Functional and Molecular Signatures of Anergy Induced by Continual B Cell Receptor Signaling 21
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 20
The B-Side of B Cells 20
Might IgA be a biomarker of disease activity in Takayasu arteritis 20
Replicative senescence prevents the differentiation of B-cells to antibody producine cells in common variable immunodeficiency 19
Recent news in the treatment of hepatitis B virus-related cryogobulinemic vasculitis 15
Correction to: management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC) 15
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 14
Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC) 13
Hepatitis C virus-associated indolent B-cell lymphomas: A review on the role of the new direct antiviral agents therapy 13
Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells 12
Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases 12
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 11
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy 11
Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis 11
Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC) 10
Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature 9
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 8
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies 6
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 5
Totale 4.821
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.963
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020712 0 0 5 33 83 89 103 95 107 98 61 38
2020/2021378 28 42 21 14 12 34 6 25 73 81 34 8
2021/2022906 64 45 74 24 104 45 33 82 85 80 125 145
2022/20231.119 202 212 58 132 98 94 35 70 135 1 51 31
2023/2024695 31 97 36 64 75 144 31 36 5 81 40 55
2024/2025228 41 138 49 0 0 0 0 0 0 0 0 0
Totale 4.829